Document 0022
 DOCN  M9550022
 TI    Measles seroprevalence and vaccine response in HIV-infected adults.
 DT    9505
 AU    Wallace MR; Hooper DG; Graves SJ; Malone JL; Department of Internal
       Medicine (HIV Division), Naval Medical; Center, San Diego.
 SO    Vaccine. 1994 Oct;12(13):1222-4. Unique Identifier : AIDSLINE
       MED/95141685
 AB    Measles in HIV-infected patients can be a severe, even fatal, illness.
       The prevalence of measles seropositivity in HIV-infected adults and the
       durability of these antibody levels are uncertain. A prospective survey
       of 210 HIV-infected adults found that 95% of the adults had demonstrable
       antibodies using a standard ELISA technique. Seropositivity was no
       different in patients with CD4 counts over 400, from those with more
       advanced disease and CD4 counts under 200 (p = 0.8). Six seronegative
       patients were vaccinated and had serial antibody determinations: two of
       six (33%) patients had a durable positive antibody response at 1 year,
       and none had any observed toxicity. Vaccination of the identified
       measles-seronegative HIV-infected adults who are at high risk for
       measles is recommended, but a measurable antibody response may be
       expected in only a minority of cases.
 DE    Adult  Antibodies, Viral/*BLOOD  AIDS-Related Opportunistic
       Infections/COMPLICATIONS/IMMUNOLOGY/  PREVENTION & CONTROL  Cohort
       Studies  Female  Human  HIV Infections/COMPLICATIONS/*IMMUNOLOGY  Male
       Measles/COMPLICATIONS/IMMUNOLOGY/PREVENTION & CONTROL  Measles
       Vaccine/IMMUNOLOGY/*PHARMACOLOGY  Measles Virus/*IMMUNOLOGY  Prospective
       Studies  CLINICAL TRIAL  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).